MIPL-Logo

3decades

 

MIRA INFORM REPORT

 

 

Report No. :

506212

Report Date :

26.04.2018

 

 

IDENTIFICATION DETAILS

 

Name :

ALCARE CO LTD

 

 

Registered Office :

Arcare Central Bldg 19F, 1-2-1 Kinshi Sumidaku Tokyo 130-0013

 

 

Country :

Japan

 

 

Financials (as on) :

30.06.2017

 

 

Date of Incorporation :

May 1943

 

 

Com. Reg. No.:

0106-01-013032

 

 

Legal Form :

Limited Company

 

 

Line of Business :

Manufactures medical equipment, medical instruments, other

 

 

No. of Employees :

410

 

 

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

 

MIRA’s Rating :

A

 

Credit Rating

Explanation

Rating Comments

A

Acceptable Risk

Business dealings permissible with moderate risk of default

 

Status :

Good

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List

 

Country Name

Previous Rating

(30.09.2017)

Current Rating

(31.12.2017)

Japan

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low Risk

 

A2

Moderately Low Risk

 

B1

Moderate Risk

 

B2

Moderately High Risk

 

C1

High Risk

 

C2

Very High Risk

 

D

 

 

JAPAN - ECONOMIC OVERVIEW

 

Over the past 70 years, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (slightly less than 1% of GDP) have helped Japan develop an advanced economy. Two notable characteristics of the post-World War II economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features have significantly eroded under the dual pressures of global competition and domestic demographic change.

Measured on a purchasing power parity basis that adjusts for price differences, Japan in 2017 stood as the fourth-largest economy in the world after first-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2012. For three postwar decades, overall real economic growth was impressive - averaging 10% in the 1960s, 5% in the 1970s, and 4% in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the aftereffects of inefficient investment and the collapse of an asset price bubble in the late 1980s, which resulted in several years of economic stagnation as firms sought to reduce excess debt, capital, and labor. Modest economic growth continued after 2000, but the economy has fallen into recession four times since 2008.

Japan enjoyed an uptick in growth since 2013, supported by Prime Minister Shinzo ABE’s “Three Arrows” economic revitalization agenda - dubbed “Abenomics” - of monetary easing, “flexible” fiscal policy, and structural reform. Led by the Bank of Japan’s aggressive monetary easing, Japan is making modest progress in ending deflation, but demographic decline – a low birthrate and an aging, shrinking population – poses a major long-term challenge for the economy. The government currently faces the quandary of balancing its efforts to stimulate growth and institute economic reforms with the need to address its sizable public debt, which stands at 235% of GDP. To help raise government revenue, Japan adopted legislation in 2012 to gradually raise the consumption tax rate. However, the first such increase, in April 2014, led to a sharp contraction, so Prime Minister ABE has twice postponed the next increase, which is now scheduled for October 2019. Structural reforms to unlock productivity are seen as central to strengthening the economy in the long-run.

Scarce in critical natural resources, Japan has long been dependent on imported energy and raw materials. After the complete shutdown of Japan’s nuclear reactors following the earthquake and tsunami disaster in 2011, Japan's industrial sector has become even more dependent than before on imported fossil fuels. However, ABE’s government is seeking to restart nuclear power plants that meet strict new safety standards and is emphasizing nuclear energy’s importance as a base-load electricity source. In August 2015, Japan successfully restarted one nuclear reactor at the Sendai Nuclear Power Plant in Kagoshima prefecture, and several other reactors around the country have since resumed operations; however, opposition from local governments has delayed several more restarts that remain pending. Reforms of the electricity and gas sectors, including full liberalization of Japan’s energy market in April 2016 and gas market in April 2017, constitute an important part of Prime Minister Abe’s economic program.

Under the Abe Administration, Japan’s government sought to open the country’s economy to greater foreign competition and create new export opportunities for Japanese businesses, including by joining 11 trading partners in the Trans-Pacific Partnership (TPP). Japan became the first country to ratify the TPP in December 2016, but the United States signaled its withdrawal from the agreement in January 2017. In November 2017 the remaining 11 countries agreed on the core elements of a modified agreement, which they renamed the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP). Japan also reached agreement with the European Union on an Economic Partnership Agreement in July 2017, and is likely seek to ratify both agreements in the Diet this year.

 

Source : CIA

Company summery

 

ALCARE CO LTD

REGD NAME:   Alcare KK

MAIN OFFICE:  Arcare Central Bldg 19F, 1-2-1 Kinshi Sumidaku Tokyo 130-0013 JAPAN

                        Tel: 03-5611-7800      Fax: 03-5611-7825

 

URL:                 http://www.alcare.co.jp

E-Mail address: (Thru the URL)

 

ACTIVITIES:     Mfg of medical equipment, medical instruments, other

BRANCHES:     Sapporo Chiba, other (Tot 9)

FACTORIES:    Chiba

 

OFFICERS:       TERUSHIGE SUZUKI, PRES      Satoshi Mitsuhashi, v pres

                        Katsumi Ito, s/mgn dir               Masahisa Ishizaka, dir

                        Jundo Ishikawa, dir                    Yoshiaki Noguchi, dir

                       

Yen Amount:     In million Yen, unless otherwise stated

 

SUMMARY:      FINANCES        FAIR                             A/SALES          Yen 14,184 M

                        PAYMENTS      NO COMPLAINTS          CAPITAL           Yen 90 M

                        TREND             SLOW                           WORTH            Yen 37,250 M   

                        STARTED         1943                             EMPLOYES      410

 

 

COMMENT

 

MFG OF MEDICL EQUIPMENT.

FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.

                       

 

HIGHLIGHTS

           

The subject company is a specialized mfr of medical equipment, medical instruments, other.  Goods are exported.  Clients include hospitals, laboratories, other

 

 

FINANCIAL INFORMATION

 

Financials are only partially disclosed. 

           

The sales volume for Jun/2017 fiscal term amounted to Yen 14,184 million, a 1.42% fall from Yen 14,389 million in the previous term.  The net profit was posted at Yen 1,000 million, compared with Yen 1,350 million a year ago.

 

For the current term ending Jun 2018 the net profit is projected at Yen 1,100 million, on a 3% rise in turnover, to Yen 14,600 million.

 

The financial situation is considered FAIR and good for ORDINARY business engagements. 

 

 

REGISTRATION

    

Date Registered:   May 1943

Regd No.:         0106-01-013032 (Tokyo-Sumidaku)

Legal Status:       Limited Company (Kabushiki Kaisha)

Authorized:         720,000 shares

Issued:                180,000 shares

Sum:                   Yen 90 million

Major shareholders (%): Terushige Suzuki (100)

 

Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION

           

Activities: Manufactures medical equipment, medical instruments, other (--100%)

 

Clients: [Mfrs, wholesalers] Japan Medical Alliance, MM Corp, TS Alfresa, Mutow Inc, Konishi Medical Equipment, Shioyama Ika Corp, Iwatsuki Inc, other 

No. of accounts: 350

Domestic areas of activities: Nationwide

 

Suppliers: [Mfrs, wholesalers] Marubeni Intex, Kuraray Inc, Hirabayashi Package, other

 

Payment record: No Complaints

 

Location: Business area in Tokyo.  Office premises at the caption address are leased and maintained satisfactorily.

 

Bank References:

                        Mizuho Bank (Oshiage)

                        Shoko Chukin Bank (Chiba)

                        Relations: Satisfactory

 

 

 

 

 

FINANCES

 

 (In Million Yen)

Terms Ending:

　

30/06/2018

30/06/2017

30/06/2016

30/06/2015

Annual Sales

　

14,600

14,184

14,389

13,747

Recur. Profit

　

..

..

..

..

Net Profit

　

1,100

1,000

1,350

1,240

Total Assets

　

　

N/A

N/A

N/A

Net Worth

　

　

37,250

37,150

35,800

Capital, Paid-Up

　

　

90

90

90

Div.P.Share(¥)

　

　

0.00

0.00

0.00

<Analytical Data>

　

(%)

(%)

(%)

(%)

    S.Growth Rate

　

2.93

-1.42

4.67

5.36

    Current Ratio

　

　

..

..

..

    N.Worth Ratio

　

　

..

..

..

    N.Profit/Sales

　

7.53

7.05

9.38

9.02

Notes: Financials are only partially disclosed.

Forecast (or estimated) figures for the 30/06/2018 fiscal term.

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

INR 66.70

UK Pound

1

INR 93.14

Euro

1

INR 81.43

YEN

1

INR 0.61

                                                                  

Note : Above are approximate rates obtained from sources believed to be correct

 

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

TRU

                                                


 

RATING EXPLANATIONS

 

Credit Rating

Explanation

Rating Comments

A++

Minimum Risk

Business dealings permissible with minimum risk of default

A+

Low Risk

Business dealings permissible with low risk of default

A

Acceptable Risk

Business dealings permissible with moderate risk of default

B

Medium Risk

Business dealings permissible on a regular monitoring basis

C

Medium High Risk

Business dealings permissible preferably on secured basis

D

High Risk

Business dealing not recommended or on secured terms only

NB

New Business

No recommendation can be done due to business in infancy stage

NT

No Trace

No recommendation can be done as the business is not traceable

 

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

 

·         Financial condition covering various ratios

·         Company background and operations size

·         Promoters / Management background

·         Payment record

·         Litigation against the subject

·         Industry scenario / competitor analysis

·         Supplier / Customer / Banker review (wherever available)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.